# Edward Jr. Balestra

Edward Jr. Balestra writes about leadership and building scalable operating models for healthcare technology companies, including enterprise readiness, product strategy, and decision-making.

- Profile: https://b2binfluencer.marketing/creators/edward-jr-balestra/
- LinkedIn: https://www.linkedin.com/in/edwardbalestra
- Topics: leadership, healthcare, customer-success
- Based on 10 dated posts, latest 2026-10-01

## Summary

They are most useful for healthcare technology leaders diagnosing growth, execution, or organizational bottlenecks.

- Best for: A healthcare SaaS company needing a scalable operating model and repeatable enterprise implementation.
- Not for: Sponsored LinkedIn posts promoting a vendor product to enterprise buyers.
- Check first: Ask for relevant examples and references, plus availability, day rate and scope boundaries.

### Takeaways

- Healthcare software growth stalls from system design, not product quality.
- An enterprise contract does not prove enterprise readiness; implementation and adoption matter.
- Scaling requires clearer decision rights, not more meetings.

## Main ideas

- **Healthcare software growth stalls because of system design, not product quality**: Balestra argues that healthcare software plateaus usually reflect organisational problems, not product ones. Four patterns recur: product reports to the CTO and functions as backlog management rather than a business function responsible for positioning and turning the roadmap into revenue; the roadmap is rebuilt whenever a deal is at risk; customer success manages requests instead of expanding revenue at the executive level and feeding market insight back into the business; and product, customer success, and go-to-market operate independently, without connective tissue. The result is the same each time: every deal becomes custom, implementation slows, margins compress, and growth stalls.
- **An enterprise contract demands a new operating standard; it does not prove the company has one**: Balestra argues that the habits that win early traction — flexibility, big promises, quick adaptation, customisation for early customers, and figuring things out alongside the client — do not scale to a large health system, payer, or national provider group. Implementation cannot feel improvised, training cannot be invented live, and clients expect the vendor to know their workflows, define the rollout, identify super users, manage change, and drive adoption with discipline. Enterprise clients also expect measurable clinical, operational, or financial value, or a mix, visible quarter after quarter and carried consistently from sales promises through implementation, onboarding, customer success, support, and executive business reviews.
- **Not every request from a large customer should become the roadmap**: This priority runs through two of Balestra's posts. They write that every enterprise request cannot become the roadmap for the next two years. Product leaders must distinguish requests that create the most value from one-off preferences and market signals, and identify the few that should shape broader product strategy. Large strategic customers deserve attention and may need dedicated capacity, but that is a governance question, not a reason to let deal pressure set direction. A roadmap that changes whenever a deal is at risk, Balestra argues, is a sales support function, not a product strategy.
- **Scaling requires decision rights, not more meetings**: When a high-profile client wants to renegotiate or two functions clash over development priorities, the default is often to schedule one meeting after another until a month passes without a decision or an owner. Balestra draws a distinction: debate needs a forum, the right people should pressure-test options, and meetings are not inherently wrong. The failure is using them to substitute for decision rights. Seeking full leadership-team alignment on every meaningful decision kills speed. Scaling companies need to document who owns each decision, who provides input, who needs to be informed, and when debate ends.
- **Executives own business outcomes, not just a well-run function**: Balestra distinguishes two kinds of accountability. At director level, most of the role remains internal: whether the team executes, is structured correctly, and is improving process, quality, and consistency. At VP level, the job becomes external and commercial: what the market is saying, which outcomes customers care about, where value is created or lost, and how the function connects to revenue, retention, margin, adoption, implementation, and customer value realisation. A function can look healthy while the business is not. The question shifts from whether your team is performing to whether the business is — and what you are doing to connect the pieces.

## Work to read

- [Most Healthcare SaaS Companies Don't Stall Because of Product. They Stall Because They Never Build a Real Operating Model](https://www.linkedin.com/posts/edwardbalestra_most-healthcare-saas-companies-dont-stall-activity-7450213146935459840-JXO9)
- [Selling to an enterprise customer is not the same as being enterprise-ready](https://www.linkedin.com/posts/edwardbalestra_selling-to-an-enterprise-customer-is-not-activity-7465430555137024000-k9lY)
- [Scaling doesn't require more meetings. It requires clearer decision rights.](https://www.linkedin.com/posts/edwardbalestra_scaling-doesnt-require-more-meetings-it-activity-7457485912084508672-SgSV)
- [Real executive leadership is not functional management. It is business outcome ownership.](https://www.linkedin.com/posts/edwardbalestra_real-executive-leadership-is-not-functional-activity-7460702130157486080-dHU1)

## Partnerships

The material reviewed for Edward Jr. Balestra contains no documented sponsorship or partnership offer. None of the four LinkedIn posts carries a brand partnership, sponsored-content label, or disclosed commercial collaboration, and the profile listing shows no media kit, rate card, audience deck, or partnership terms. They write as a practitioner about operating models, enterprise readiness, and executive leadership in healthcare technology; the posts read as commentary rather than sponsored placements. The only verified contact route is the LinkedIn profile, a general professional channel rather than a dedicated partnership inquiry line. Buyers should ask directly about partnership terms before planning spend.

## Alternatives

- Jessica Quintana, PhD, MPA: Choose Quintana when the constraint is healthcare operations rather than software delivery. Her two posts target people hiring senior healthcare operators and describe 21 years in healthcare, beginning with patients in clinical settings and clinical research before moving into enterprise operations, payer strategy, provider network development and value-based care across Commercial, Medicare and Medicaid. She cites scaling national programs, leading multi-state operations, growing provider networks, opening medical centers, and working within P&L and margin pressure. If the client's six-month problem is payer relationships, network growth, or cost and MLR performance, her stated experience is closer to that challenge than Balestra's writing, which stays on the software side of the same industry.
- Ianthe Hernandez: Choose Hernandez when the breakdown is downstream of strategy: adoption, handoffs and process trust. Her posts describe that layer in detail. One follows a sales conversation and implementation plan that go well, then a handoff that loses context: goals are not carried forward, risks go undocumented, support issues are disconnected from adoption, customer success lacks visibility into technical blockers, and the customer feels friction without being able to name it. The other explains that a CRM can be configured correctly and still fail when users do not trust the surrounding workflow, leading them to work around it in spreadsheets and inboxes. If the client's symptom is deals that implement but do not get adopted, or a process people quietly bypass, this is a tighter, easier-to-scope engagement than a broad operating-model mandate.
- Erica Geil: Choose Geil when the consequential decision is a technology one. Her posts reframe the familiar question of whether a company is big enough to need a CIO as whether technology decisions have become consequential enough to require CIO-level judgment. She sets out three working models: a full-time CIO, a fractional CIO alongside the executive team through growth or transformation, and a micro-fractional CIO brought in around one high-consequence decision. The second post applies the same test to 2027 AI budgets, asking what outcome the money is meant to create, whether the data and processes support the use case, what new risk is introduced, who owns the initiative, and what funding it would displace. If the client is about to commit budget to AI, replace or consolidate a platform, or set up technology governance and decision rights, she addresses that decision directly. She is also the only one of the three whose posts state plainly that she sells fractional engagements and currently has some availability.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/